No profile data available.
Zentalis Pharmaceuticals, Inc. (ZNTL) is a healthcare company in the additional cancer treatment drugs industry, based in San Diego, United States, with about 106 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$137.06 million. Its market capitalization was $259.04 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Zentalis Pharmaceuticals reported $0 in revenue for fiscal year 2025, down 100.0% from $67.43 million in fiscal year 2024.
$259.04 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include CytoDyn Inc. (CYDY), Northwest Biotherapeutics, Inc. (NWBO), Fate Therapeutics, Inc. (FATE), Immuneering Corporation (IMRX).